Last reviewed · How we verify

Sustained-Release Desvenlafaxine Hydrochloride

Jiangsu Hansoh Pharmaceutical Co., Ltd. · Phase 2 active Small molecule

Sustained-Release Desvenlafaxine Hydrochloride is a Small molecule drug developed by Jiangsu Hansoh Pharmaceutical Co., Ltd.. It is currently in Phase 2 development.

At a glance

Generic nameSustained-Release Desvenlafaxine Hydrochloride
SponsorJiangsu Hansoh Pharmaceutical Co., Ltd.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sustained-Release Desvenlafaxine Hydrochloride

What is Sustained-Release Desvenlafaxine Hydrochloride?

Sustained-Release Desvenlafaxine Hydrochloride is a Small molecule drug developed by Jiangsu Hansoh Pharmaceutical Co., Ltd..

Who makes Sustained-Release Desvenlafaxine Hydrochloride?

Sustained-Release Desvenlafaxine Hydrochloride is developed by Jiangsu Hansoh Pharmaceutical Co., Ltd. (see full Jiangsu Hansoh Pharmaceutical Co., Ltd. pipeline at /company/jiangsu-hansoh-pharmaceutical-co-ltd).

What development phase is Sustained-Release Desvenlafaxine Hydrochloride in?

Sustained-Release Desvenlafaxine Hydrochloride is in Phase 2.

Related